During the past decade, Beijing Hospital conducted 177 clinical trials. In the 10-year time frame, 177 clinical trials started and 19 clinical trials were completed, i.e. on average, 10.7% percent of trials that started reached the finish line to date. In the past 5 years, 114 clinical trials started and 14 clinical trials were completed. i.e. 12.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Beijing Hospital" #1 sponsor was "Beijing Hospital" with 16 trials, followed by "Peking Union Medical College Hospital" with 8 trials sponsored, "Boehringer Ingelheim" with 7 trials sponsored, "Eli Lilly and Company" with 7 trials sponsored and "Janssen Research & Development, LLC" with 7 trials sponsored. Other sponsors include 168 different institutions and companies that sponsored additional 122 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Beijing Hospital" #1 collaborator was "Beijing Hospital" with 21 trials as a collaborator, "West China Hospital" with 6 trials as a collaborator, "Fudan University" with 5 trials as a collaborator, "Nanfang Hospital of Southern Medical University" with 5 trials as a collaborator and "Peking University People's Hospital" with 5 trials as a collaborator. Other collaborators include 293 different institutions and companies that were collaborators in the rest 222 trials.

According to Clinical.Site data, the most researched conditions in "Beijing Hospital" are "Coronary Artery Disease" (6 trials), "Breast Cancer" (5 trials), "Type 2 Diabetes" (4 trials), "Alzheimer Disease" (3 trials) and "Branch Retinal Vein Occlusion" (3 trials). Many other conditions were trialed in "Beijing Hospital" in a lesser frequency.

Most popular intervention types in "Beijing Hospital" are "Drug" (143 trials), "Device" (25 trials), "Other" (18 trials), "Procedure" (15 trials) and "Biological" (12 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (28 trials), "Capecitabine" (4 trials), "Normal Saline" (3 trials), "Rituximab" (3 trials) and "Tislelizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Beijing Hospital" are 194 trials for "All" genders, 14 trials for "Male" genders and 9 trials for "Female" genders.

Currently, there are 101 active trials in "Beijing Hospital". 2 are not yet recruiting, 70 are recruiting, 28 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 61 completed trials in Beijing Hospital, 2 suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Beijing Hospital, 16 "Phase 1" clinical trials were conducted, 35 "Phase 2" clinical trials and 78 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 25 trials, and there were also 31 trials that are defined as “Not Applicable".

Beijing Hospital has several departments that took part in Clinical trials: "Department of respiratory and critical care medicine,Beijing Chao-yang Hospital" - 7 trials, "Beijing Chaoyang District Centers for Disease Control and Prevention" - 4 trials, "Daxing District Center for Disease Prevention and Control" - 2 trials